BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsEarnings

-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine - -CASGEVY ® momentum accelerating; nearly 300 patients have been referred to Authorized

Related news

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

SGMOSangamo Therapeutics, Inc.2026-05-14 20:01 EST

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
59.50 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States